Probiotic Formulation for Patients With Bipolar or Schizophrenia Spectrum Disorder: A Double-Blind, Randomized Placebo-Controlled Trial
Schizophrenia Bulletin · 10.11.2025 · 51 (6) · 1568-1580
DOI: 10.1093/schbul/sbae188 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Schizophrenia Bulletin, online erschienen am 06.11.2024. Verfasst von Jenny Borkent und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Bipolar Disorder, Cognitive Dysfunction, Gastrointestinal Microbiome, Outcome Assessment, Health Care. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Stanley Medical Research Institute, ZonMw.
Abstract (Originalsprache)
Background and Hypothesis Probiotic augmentation offers a promising treatment for bipolar disorder (BD) and schizophrenia spectrum disorder (SSD). By targeting microbiome deviations, they may improve both gut and brain health. Study Design In this double-blind, randomized, placebo-controlled trial with the multi-strain probiotic formulation Ecologic BARRIER, we aimed to improve psychiatric and cognitive symptoms, intestinal permeability, and gastrointestinal symptoms in patients with BD or SSD. A total of 131 patients were randomized 1:1 to receive either the probiotic supplement (n = 67) or a placebo (n = 64) for 3 months, in addition to treatment-as-usual. The primary outcomes were symptom severity assessed by the Brief Psychiatric Rating Scale and cognitive functioning by the Brief Assessment of Cognition in Schizophrenia. Study Results No significant effect of probiotics was observed on psychiatric symptoms, but borderline significant improvement was observed in the cognition category of verbal memory (Linear Mixed Model (LMM) 0.33; adjusted P = .059). Probiotics beneficially affected markers of intestinal permeability and inflammation, including zonulin (LMMserum = −18.40; adjusted P = .002; LMMfecal = −10.47; adjusted P = .014) and alpha-1 antitrypsin (LMM 9.26; adjusted P = .025). Indigestion complaints significantly decreased in male participants in the probiotics group (LMM = −0.70; adjusted P = .010). Adverse events were similar between groups. Conclusions Our study observed significant advantages of probiotics for gut health in BD and SSD, with excellent safety and tolerability. A borderline effect on verbal memory was also indicated. These results underscore the need for further research into microbiome-targeted interventions for patients with complex brain disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Sciences, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
- Department of Psychiatry, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
- Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9713 GZ, Groningen, The Netherlands.
ORCID-Profile: Jenny Borkent
Förderung
- Stanley Medical Research Institute
- ZonMw
Zitieren
APA
Borkent, J., Ioannou, M., Neijzen, D., Haarman, B. C. M., & Sommer, I. E. C. (2025). Probiotic Formulation for Patients With Bipolar or Schizophrenia Spectrum Disorder: A Double-Blind, Randomized Placebo-Controlled Trial. Schizophrenia Bulletin, 51(6), 1568-1580. https://doi.org/10.1093/schbul/sbae188
Vancouver
Borkent J, Ioannou M, Neijzen D, Haarman BCM, Sommer IEC. Probiotic Formulation for Patients With Bipolar or Schizophrenia Spectrum Disorder: A Double-Blind, Randomized Placebo-Controlled Trial. Schizophrenia Bulletin. 2025;51(6):1568-1580. doi:10.1093/schbul/sbae188
BibTeX
@article{Borkent2025,
author = {Borkent, Jenny and Ioannou, Magdalini and Neijzen, Dorien and Haarman, Bartholomeus C M and Sommer, Iris E C},
title = {Probiotic Formulation for Patients With Bipolar or Schizophrenia Spectrum Disorder: A Double-Blind, Randomized Placebo-Controlled Trial},
journal = {Schizophrenia Bulletin},
year = {2025},
volume = {51},
number = {6},
pages = {1568--1580},
doi = {10.1093/schbul/sbae188}
}
EUVIMED